

Revision date: 02-Jan-2007 Version: 1.1 Page 1 of 7

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Nicergoline Coated Tablets

Trade Name: Sermion Coated Tablets, 5 mg, 10 mg

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as cognition activator

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Nicergoline	27848-84-6	248-694-6	5 or 10 mg***
Titanium dioxide	13463-67-7	236-675-5	*
Magnesium stearate	557-04-0	209-150-3	*
Talc (non-asbestiform)	14807-96-6	238-877-9	*
Sucrose	57-50-1	200-334-9	*
Microcrystalline cellulose	9004-34-6	232-674-9	*

Ingredient	CAS Number	EU EINECS List	%
Sandarac Gum	9000-57-1	232-547-8	*
Carnauba wax	8015-86-9	232-399-4	*
Carboxymethylcellulose sodium	9004-32-4	Not listed	*
Magnesium carbonate	39409-82-0	Not listed	*
Acacia	9000-01-5	232-519-5	*
Dibasic calcium phosphate, dihydrate USP	7789-77-7	Not listed	*
ROSIN	8050-09-7	232-475-7	*

Additional Information: * Proprietary

*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

3. HAZARDS IDENTIFICATION

Appearance: White tablets

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: May cause drowsiness, insomnia, nervousness, and dizziness.

Material Name: Nicergoline Coated Tablets

Page 2 of 7
Revision date: 02-Jan-2007

Version: 1.1

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including

hypotension (low blood pressure), dizziness, headache and drowsiness. Adverse effects associated with the therapeutic use include skin rash and gastrointestinal disturbances.

EU Indication of danger: Not classified

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

4. FIRST AID MEASURES

Eye Contact: If irritation occurs or persists, get medical attention. Flush eyes with water as a precaution

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, oxides of nitrogen and bromine-

containing compounds

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: No data available

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Nicergoline Coated Tablets

Page 3 of 7
Revision date: 02-Jan-2007

Version: 1.1

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with

eyes.

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and

flames.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Titanium dioxide

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA

Australia TWA = 10 mg/m³ TWA

Magnesium stearate

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals

Australia TWA = 10 mg/m³ TWA

Talc (non-asbestiform)

OSHA - Final PELs - Table Z-3 Mineral D: = 20 mppcf TWA
ACGIH Threshold Limit Value (TWA) = 2 mg/m³ TWA

Australia TWA = 2.5 mg/m³ TWA containing no asbestos fibers

Sucrose

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

= 5 mg/m³ TWA = 10 mg/m³ TWA = 10 mg/m³ TWA

Microcrystalline cellulose

Australia TWA

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

= 5 mg/m³ TWA = 10 mg/m³ TWA

ACGIH Threshold Limit Value (TWA)
Australia TWA

ACGIH Threshold Limit Value (TWA)

= 10 mg/m³ TWA

ROSIN

ACGIH - Sensitizer Designation Sensitizer

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Nicergoline

Pfizer Occupational Exposure OEB3 (control exposure to the range of >10ug/m³ to < 100ug/m³)

Band (OEB):

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Use process

containment, local exhaust ventilation, or other engineering controls to maintain airborne levels

within the OEB range.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Material Name: Nicergoline Coated Tablets

Page 4 of 7
Revision date: 02-Jan-2007

Version: 1.1

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: None required under normal conditions of use. If airborne exposures are within or exceed the

Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection

factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Tablet Color: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: Not determined

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg Rat Subcutaneous LD 50 50 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m³

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Carboxymethylcellulose sodium

Mouse Oral LD50 > 27,000 mg/kg Rat Oral LD50 27,000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Nicergoline

Rat Oral LD 50 1193 mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Material Name: Nicergoline Coated Tablets Page 5 of 7
Revision date: 02-Jan-2007 Version: 1.1

Revision date: 02-Jan-2007 Version: 1.1

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

<u>Irritation / Sensitization: (Study Type, Species, Severity)</u>

Acacia

Eye Irritation Rabbit Severe

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Carboxymethylcellulose sodium

13 Week(s) Rat Oral 227 g/kg LOAEL Liver, Kidney, Ureter, Bladder

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Nicergoline

Embryo / Fetal Development Rat Oral Not teratogenic

Embryo / Fetal Development Rabbit Fetotoxicity

Embryo / Fetal Development Rat Intramuscular Not Teratogenic

Carcinogen Status: See below

Titanium dioxide

IARC: Group 2B OSHA: Present

Talc (non-asbestiform)

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Material Name: Nicergoline Coated Tablets

Page 6 of 7
Revision date: 02-Jan-2007

Version: 1.1

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Nicergoline

Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

EU EINECS List 248-694-6

Sandarac Gum

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
232-547-8

Titanium dioxide

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Fresent

EU EINECS List

236-675-5

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

209-150-3

Talc (non-asbestiform)

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
238-877-9

Carnauba wax

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
232-399-4

Sucrose

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS List200-334-9

Material Name: Nicergoline Coated Tablets

Page 7 of 7
Revision date: 02-Jan-2007

Version: 1.1

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-674-9

Carboxymethylcellulose sodium

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

Magnesium carbonate

Australia (AICS): Present

Acacia

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
232-519-5

Dibasic calcium phosphate, dihydrate USP

Australia (AICS): Present

ROSIN

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
232-475-7

16. OTHER INFORMATION

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard

Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section

10 - Stability and Reactivity. Updated Section 13 - Disposal Considerations.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet